The Association of British Neurologists' myasthenia gravis guidelines.

{"article_title":"The Association of British Neurologists' myasthenia gravis guidelines.","author":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D","journal_title":"Annals of the New York Academy of Sciences","issn":"1749-6632","isbn":"","publication_date":"2018-01-01","volume":"1412","issue":"1","first_page":"166","page_count":"","accession_number":"29121404","doi":"","publisher":"New York Academy of Sciences","doctype":"Journal Article","subjects":"United Kingdom; Myasthenia Gravis therapy; Evidence-Based Medicine; Expert Testimony; Humans; Neurology; Societies, Medical; United Kingdom","interest_area":["Neurology"],"abstract":"Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to receive suboptimal treatment. A myasthenia gravis guidelines group was therefore established under the aegis of the Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available and established best practice where evidence is unavailable. It is not possible to consider all the potential decisions in managing MG without resorting to opinion rather than evidence. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians in using the right treatments in the right order and in optimizing the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines. \u00a9 2017 New York Academy of Sciences.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=29121404","isPdfLink":true,"isSAML":false,"an":"29121404","number_other":"","type_pub":"","issn_electronic":"1749-6632","languages":"English","language":"eng","date_entry":"","date_update":"","titleSource":"Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2018 Jan; Vol. 1412 (1), pp. 166-169. Date of Electronic Publication: 2017 Nov 09.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2018-01-01","description":"Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to receive suboptimal treatment. A myasthenia gravis guidelines group was therefore established under the aegis of the Association of British Neurologists. These guidelines attempt to steer a path between evidence-based practice where available and established best practice where evidence is unavailable. It is not possible to consider all the potential decisions in managing MG without resorting to opinion rather than evidence. Where there is insufficient evidence or a choice of options, the guidelines invite the clinician to seek the opinion of a myasthenia expert. The guidelines support clinicians in using the right treatments in the right order and in optimizing the use of well-known therapeutic agents. Clinical practice can be audited against these guidelines.<br \/> (© 2017 New York Academy of Sciences.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=29121404&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D","header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"29121404","RelevancyScore":"830","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"830.118103027344"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=29121404&authtype=shib&custid=ns346513&group=main&profile=eds","physicalDescription":{"Pagination":{"StartPage":"166"}},"additionalInfo":{"Authored_By":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D","Journal_Info":"Publisher: New York Academy of Sciences Country of Publication: United States NLM ID: 7506858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1749-6632 (Electronic) Linking ISSN: 00778923 NLM ISO Abbreviation: Ann N Y Acad Sci","Publication_Type":"Journal Article; Practice Guideline","Published_Date":"2018-01-01","Source":"Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2018 Jan; Vol. 1412 (1), pp. 166-169. Date of Electronic Publication: 2017 Nov 09.","Languages":"English","Electronic_ISSN":"1749-6632","MeSH_Terms":"Myasthenia Gravis\/*therapy, Evidence-Based Medicine ; Expert Testimony ; Humans ; Neurology ; Societies, Medical ; United Kingdom","Subjects":"Evidence-Based Medicine, Expert Testimony, Humans, Neurology, Societies, Medical, United Kingdom, Myasthenia Gravis therapy","Title_Abbreviations":"Annals of the New York Academy of Sciences","Volume":"1412"}}